Table 3.
Parameter | CLfG | CLfS | CLfO | VP | VG | VS | VO | CLRP |
---|---|---|---|---|---|---|---|---|
CLfS | 0.37 [0.036 to 0.69] | |||||||
CLfO | 0.49 [0.16 to 0.80] | 0.054 [−0.33 to 0.54] | ||||||
VP | 0.35 [− to 0.65] | −0.20 [−0.59 to 0.36] | 0.18 [−0.38 to 0.67] | |||||
VG | 0.60 [0.14 to 0.83] | 0.032 [−0.30 to 0.50] | 0.42 [−0.0083 to 0.75] | 0.43 [−0.50 to 0.75] | ||||
VS | 0.19 [−0.35 to 0.77] | 0.64 [0.10 to 0.83] | −0.10 [−0.50 to 0.45] | 0.28 [−0.51 to 0.57] | 0.13 [−0.31 to 0.63] | |||
VO | −0.10 [−0.42 to 0.59] | −0.40 [−0.72 to 0.37] | 0.44 [−0.24 to 0.75] | 0.53 [−0.37 to 0.85] | 0.15 [−0.14 to 0.57] | −0.14 [−0.47 to 0.44] | ||
CLRP | 0.041 [−0.46 to 0.51] | −0.033 [−0.41 to 0.49] | −0.14 [−0.51 to 0.43] | 0.20 [−0.44 to 0.72] | −0.036 [−0.59 to 0.42] | −0.0082 [−0.55 to 0.60] | −0.11 [−0.65 to 0.59] | |
CLRG,CLRS, CLROb | 0.52 [0.29 to 0.73] | 0.73 [0.35 to 0.91] | 0.28 [−0.37 to 0.68] | 0.22 [−0.25 to 0.57] | 0.23 [−0.16 to 0.57] | 0.46 [−0.065 to 0.71] | −0.30 [−0.72 to 0.55] | 0.33 [−0.068 to 0.74] |
CLfG, CLfS, and CLfO represent, respectively, formation (hepatic) clearances for paracetamol-glucuronide, paracetamol-sulfate, and the oxidative pathway metabolites; VP, VG, VS, and VO represent, respectively, volumes of distribution for paracetamol, paracetamol-glucuronide, paracetamol-sulfate, and the oxidative pathway metabolites; CLRP, CLRG, CLRS, and CLRO represent, respectively, renal clearances for unchanged paracetamol, paracetamol-glucuronide, paracetamol-sulfate, and the oxidative pathway metabolites
Data are presented as: correlation point estimate from the final model fit [bootstrap 95 % confidence interval]. Bootstrap success rate was 77 % (n = 153 out of 200)
Correlations in between-subject variability for CLRG, clRS, and CLRO were observed to be high and were fixed to one